Chronic Cough Clinical Trials

Find Chronic Cough Clinical Trials Near You

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Chronic Cough in Participants With Idiopathic Pulmonary Fibrosis

Status: Recruiting
Location: See all (15) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The primary purpose is to evaluate the safety and efficacy of NAL ER for the treatment of chronic cough in participants with Idiopathic Pulmonary Fibrosis (IPF).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Healthy Volunteers: f
View:

• Diagnosis of IPF as determined by the Investigator based on American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) clinical practice guidelines.

• Chronic cough for ≥8 weeks prior to Screening.

• PGI-Severity Score ≥ 2 at Screening.

• Forced vital capacity (FVC) ≥40 percent (%) of predicted at Screening.

• Diffusing capacity for carbon monoxide (DLCO) ≥25% of predicted during Screening or within 12 weeks prior to Screening.

• Participants who are currently taking antifibrotic medication (e.g., nintedanib, pirfenidone, nerandomilast) should be on a stable dose for at least 6 weeks prior to the Baseline Visit.

Locations
United States
California
Newportnativemd, Inc.
RECRUITING
Newport Beach
Palmtree Clinical Research
RECRUITING
Palm Springs
Paradigm Clinical Research Centers, Inc. - Redding
RECRUITING
Redding
Colorado
Critical Care Pulmonary and Sleep Associates (Ccpsa) - West Clinic
RECRUITING
Lakewood
Florida
Meris Clinical Research
RECRUITING
Brandon
Pulmonary Specialists of The Palm Beaches
RECRUITING
Loxahatchee Groves
Clinical Research and Associates, Inc.
RECRUITING
Miami
Coastal Pulmonary & Critical Care, PLC
RECRUITING
St. Petersburg
Missouri
Hannibal Regional Hospital
RECRUITING
Hannibal
North Carolina
Clinical Research of Gastonia (CRG)
RECRUITING
Gastonia
Pennsylvania
Clinical Research Associates of Central, PA, LLC
RECRUITING
Dubois
South Carolina
Anmed Medical Center
RECRUITING
Anderson
Texas
Horizon Clinical Research Group
RECRUITING
Cypress
El Paso Pulmonary Association, PA
RECRUITING
El Paso
Elevate Clinical Research
RECRUITING
Houston
Contact Information
Primary
Paula Buckley
Paula.Buckley@trevitherapeutics.com
(203) 304-2499
Time Frame
Start Date: 2026-06-29
Estimated Completion Date: 2028-07
Participants
Target number of participants: 306
Treatments
Experimental: NAL ER 54 mg
Participants will undergo a 2-week blinded titration period followed by a fixed dose treatment period receiving NAL ER 54 milligrams (mg) twice daily (BID) for 52 weeks.
Placebo_comparator: Placebo
Participants will undergo a 2-week blinded titration period followed by a fixed dose treatment period receiving a matching placebo BID for 52 weeks.
Sponsors
Leads: Trevi Therapeutics

This content was sourced from clinicaltrials.gov